… dacomitinib as initial systemic therapy in clinically and molecularly selected patients with
advanced non-small-cell lung cancer… Here, first-line treatment with dacomitinib 30–45 mg per …

… that in the single-arm phase 2 ARCHER 1017 study of dacomitinib as first-line treatment in
patients with advanced non-small-cell lung cancer (NSCLC), the subgroup of patients with an …

… supported dacomitinib to be an ideal first line therapy for … of dacomitinib remains to be
determined. Our article will make a comprehensive review for the clinical application of dacomitinib …

… pending, the current clinical development of dacomitinib is largely focused on EGFR-mutant…
data of dacomitinib in advanced NSCLC. We discuss the potential role of dacomitinib in …

… systemic anti-cancer therapy in the second line, although a small … of dacomitinib and
subsequent systemic anti-cancer … dacomitinib in patients with EGFR-positive NSCLC in Japan. …

… Dacomitinib is an irreversible pan-EGFR family tyrosine kinase … cell lung cancer showed
favourable efficacy for dacomitinib compared with erlotinib. We aimed to compare dacomitinib …

… Finally, an international, multicenter, phase II trial is assessing the safety and efficacy of
dacomitinib, with or without dose titration, as first line for advanced NSCLC with EGFR activating …

… First-line dacomitinib was associated with significant prolongation of PFS and improved
OS … The AE profiles of dacomitinib and gefitinib in Asian patients were consistent with the …

… date illustrate side effects for dacomitinib similar to its first-generation counterparts. However,
… In the first-line setting, dacomitinib often required dose reduction from the 45 mg daily dose …

… The updated data with a median OS of 34.1 months demonstrate its superior efficacy over
gefitinib first line. However, the clinical benefit must be carefully balanced with the increased …